Compare ProShares Ultra QQQ ETF (QLD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Recursion Pharmaceuticals Inc — how do they compare? ProShares Ultra QQQ ETF trades at $89.91, while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| QLD | RXRX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $100.53 | $6.79 |
52-Week Low | $57.16 | $2.84 |
Market Cap | — | $1.86B |
Enterprise Value | — | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD (ProShares Ultra QQQ ETF) trades at $90.53, down 0.17% with a bullish technical signal from moving averages. The ETF has delivered over 10,000% total return since inception, demonstrating powerful compounding. Recent institutional buying includes 180 Wealth Advisors increasing their position by 29.4% in Q2 2026. Technical indicators show strong moving average support but neutral oscillators, with key support at $88-90 and resistance at $91-93 levels.
As a daily leveraged ETF tracking the Nasdaq-100, QLD offers amplified exposure to large-cap tech but carries inherent volatility risks. The current neutral RSI and ADX suggest consolidation near support levels. Institutional accumulation and strong historical performance support long-term growth potential, though leveraged structure requires careful risk management during market turbulence.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
